Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023 Gritstone prioritizing GRANITE; expanding Phase 2 from. | May 11, 2023
EMA CONTRADICTS HIS VACCINE’S EXPERT: RARE THROMBOSIS! BUSINESS MUST CONTINUE: WOMEN CAN EVEN DIED!
The “benefits” of the AstraZeneca vaccine “outweigh the risks”. The EMA reiterates this in a note at the end of its evaluation. “Rare events” of cerebral thrombosis “are very rare side effects” of the AstraZeneca vaccine. This was reported by the EMA in a note. “EMA reminds healthcare professionals and people receiving the vaccine to remain aware of the possibility that very rare cases of blood clots combined with low blood platelet levels occur within 2 weeks of vaccination,” writes the European Agency in the note. “So far, the majority of reported cases have occurred in women under the age of 60 within 2 weeks of vaccination. Based on the evidence currently available, specific risk factors have not been confirmed.” This is what the Italian press agency ANSA, which has always been a media sponsor of the AstraZeneca vaccine, half-Italian (read below to unde
“It is possible, for greater precaution, that the European Medicines Agency Ema indicates that for a certain category it is better not to use the AstraZeneca anti-Covid vaccine”. The Italian Undersecretary of Health Pierpaolo Sileri said on Radio 24, however, specifying that “this also happened for many other drugs” and that in the case of AstraZeneca the vaccine was used “in an extremely high number of subjects, while thrombotic events few reported are very few “.
The UK drug agency (MHRA) is also considering a proposal to restrict the use of the Oxford-AstraZeneca vaccine for young people. This was reported by the British television channel 4, citing informed sources. This occurs despite the fact that the vaccine, produced thanks to the vector of Chimpanzee Adenovirus provided by Park Science in Pomezia (Rome), is the only one of English origin, as the Anglo-Swedish multinational AstraZeneca has long been based in Cambridge.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 .
Vaccitech LimitedFebruary 1, 2021 GMT
OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with chronic hepatitis B (CHB) infection. The study plans to enroll 64 patients in South Korea, Taiwan and the UK.
New Delhi, Jan 8 : Amid the debate over efficacy of the Covid vaccines approved by the country's drug regulator, the Indian Medical Association has come